Related Experiment Video
Updated: May 22, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis
Ko-Ming Lin1, Jing-Chi Lin, Wen-Yi Tseng
1Division of Allergy and Immunology and Rheumatology, Chang Gung Memorial Hospital, Chia-yi, Taiwan.
Abstract:
The B-cell depletion agent rituximab (RTX) is used in lymphoma and rheumatoid arthritis (RA), and there have been several case reports of an RTX-induced reactivation of hepatitis C virus in patients with lymphoma. However, there have been no papers detailing hepatitis C virus reactivation after RTX therapy in a patient with RA. Here we report a case of RTX-induced hepatitis C virus reactivation in a patient with RA. Physicians should be aware that a close follow-up of liver function and viral load is mandatory after RTX therapy in patients with RA and concomitant hepatitis C.
Related Concept Videos
Hepatitis
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Hypersensitivity Reactions: Cytolytic Reactions

